Skip to main content Skip to main navigation menu Skip to site footer

Management of critical patient infected with extended spectrum beta-lactamase (ESBL) producing Escherichia Coli

  • Maya Permatasari Suyata ,
  • Syafri Kamsul Arif ,
  • A Husni Tanra ,
  • Faisal Muchtar ,


Introduction : Antibiotics has been widely used in medical practices nowadays. Antibiotics usage is often massively performed and sometimes not as indicated. Un-judicious and overuse of antibiotics that is not correlated with clinical pathways could result in antimicrobial resistance. Extended Spectrum Beta-Lactamase (ESBL) is an enzyme that has a capability of hydrolysing and deactivate Penicillin group antibiotics, 1st, 2nd, 3rd generation cephalosporin, as well as Monobactam antibiotics, further will cause resistance to those antibiotics. These matters will make it difficult to choose antibiotics. This article will discuss patients with Escherichia coli infection with ESBL in septic shock and its management.

Case Presentation: Thirty five years old female with BMI 22 Kg/m2 was admitted to ICU with septic shock caused by infected sacral pressure sore. She has a history of traffic accidents and was mechanical ventilated 6 months ago. We performed septic shock management according to the Surviving Sepsis Campaign recommendation along with other supportive management. Macro (temperature, heart rate, mean arterial blood pressure) and micro haemodynamic (lactate, pCO2 gap, central venous pressure, vena cava inferior diameter) changed on day 3. We change the antibiotic according to the culture result. Escherichia Coli was found in blood culture with ESBL. The antibiotics were Amikacin combined with Tigecycline. Improvement was seen on the fifth day, then stopped the vasopressor, on day six weaned the mechanical ventilation.

Conclusion: Resuscitation and rapid source control of infection focus, combined with appropriate antibiotic choice become the key principle in managing patients with septic shock caused by Escherichia coli with ESBL.


  1. Sloan C, Edwards CJ. Extended Spectrum Beta-Lactamase. Emerg Manag Infect Dis Second Ed. 2018;1(1):552–5.
  2. Mahmud ZH, Kabir MH, Ali S, Moniruzzaman M, Imran KM, Nafiz TN, et al. Extended-Spectrum Beta-Lactamase-Producing Escherichia coli in Drinking Water Samples From a Forcibly Displaced, Densely Populated Community Setting in Bangladesh. Front Public Heal. 2020;8:1–14.
  3. Teklu DS, Negeri AA, Legese MH, Bedada TL, Woldemariam HK, Tullu KD. Extended-spectrum beta-lactamase production and multi-drug resistance among Enterobacteriaceae isolated in Addis Ababa, Ethiopia. Antimicrob Resist Infect Control. 2019;8(1):1–12.
  4. Antimikroba B, Padang MD, Fadil M, Rasyid R, Hidayat M. Gambaran Sensitivitas Bakteri Penghasil Enzim Extended Spectrum Beta-lactamase terhadap. Indones J Heal Sci. 2019;87–94.
  5. Elmawati EW, Pratiwi DIN, Muthmainah N, Biworo A. Antibiotic Susceptibility Pattern of Extended-Spectrum Beta-Lactamase-Producing Klebsiella Pneumoniae and Escherichia Coli. Indones J Clin Pathol Med Lab. 2021;27(3):282–8.
  6. Shaikh S, Fatima J, Shakil S, Rizvi SMD, Kamal MA. Antibiotic resistance and extended spectrum beta-lactamases: Types, epidemiology and treatment. Saudi J Biol Sci. 2015;22(1):90–101.
  7. Goyena R. Universitas Gadjah Mada, 2017 | Diunduh dari Hub Regulasi Diri Dalam Belajar Dan Efikasi Diri Akad Dengan Prokrastinasi Pada Mhs Akhir. 2017;3(1984):1–13.
  8. Peetermans M, de Prost N, Eckmann C, Norrby-Teglund A, Skrede S, De Waele JJ. Necrotizing skin and soft-tissue infections in the intensive care unit. Clin Microbiol Infect. 2020;26(1):8–17.
  9. Bassetti M, Peghin M, Pecori D. The management of multidrug-resistant enterobacteriaceae. Curr Opin Infect Dis. 2016;29(6):583–94.
  10. Curcio D, Barcelona LI, Cornistein W, Bantar C, Barcan L, Bonvehí P, et al. Current Rational to Prescribe Tigecycline: Critical Analysis of the Evidence and Usage Algorithms by an Argentinean Experts Panel. Clin Med Ther. 2009;1.
  11. Shiraishi A, Gando S, Abe T, Kushimoto S, Mayumi T, Fujishima S, et al. Quick sequential organ failure assessment versus systemic inflammatory response syndrome criteria for emergency department patients with suspected infection. Sci Rep. 2021;11(1):1–9.
  12. Singer M, Deutschman CS, Seymour C, Shankar-Hari M, Annane D, Bauer M, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA - J Am Med Assoc. 2016;315(8):801–10.
  13. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Vol. 45, Critical Care Medicine. 2017. 486–552.
  14. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47(11):1181–247.
  15. Malbrain MLNG, Langer T, Annane D, Gattinoni L, Elbers P, Hahn RG, et al. Intravenous fluid therapy in the perioperative and critical care setting: Executive summary of the International Fluid Academy (IFA). Ann Intensive Care. 2020;10(1).
  16. Malbrain MLNG, Van Regenmortel N, Saugel B, De Tavernier B, Van Gaal PJ, Joannes-Boyau O, et al. Principles of fluid management and stewardship in septic shock: it is time to consider the four D’s and the four phases of fluid therapy. Ann Intensive Care. 2018;8(1).
  17. Castro R, Kattan E, Ferri G, Pairumani R, Valenzuela ED, Alegría L, et al. Effects of capillary refill time-vs. lactate-targeted fluid resuscitation on regional, microcirculatory and hypoxia-related perfusion parameters in septic shock: a randomized controlled trial. Ann Intensive Care. 2020;10(1).
  18. Wang X, Long Y, Su L, Zhang Q, Shan G, He H. Using Procalcitonin to Guide Antibiotic Escalation in Patients With Suspected Bacterial Infection: A New Application of Procalcitonin in the Intensive Care Unit. Front Cell Infect Microbiol. 2022;12:1–8.
  19. Assink-de Jong E, de Lange DW, van Oers JA, Nijsten MW, Twisk JW, Beishuizen A. Stop Antibiotics on guidance of Procalcitonin Study (SAPS): A randomised prospective multicenter investigator-initiated trial to analyse whether daily measurements of procalcitonin versus a standard-of-care approach can safely shorten antibiotic duration . BMC Infect Dis. 2013;13(1).
  20. Plata-Menchaca EP, Ferrer R. Procalcitonin Is Useful for Antibiotic Deescalation in Sepsis. Crit Care Med. 2021;49(4).
  21. Yu WL, Lee NY, Wang JT, Ko WC, Ho CH, Chuang YC. Tigecycline therapy for infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae in critically ill patients. Antibiotics. 2020;9(5):1–17.
  22. Pangalila FJV, Soepandi PZ, Albandjar CA, Sukesih L, Enty. Pedoman Antibiotik Empirik di Unit Rawat Intensif. 2019: 31.
  23. Taylor R, Baker A. Enteral nutrition in critical illness: Part One. Paediatr Nurs. 1999;11(7):16–20.

How to Cite

Suyata, M. P., Arif, S. K., Tanra, A. H., & Muchtar, F. (2023). Management of critical patient infected with extended spectrum beta-lactamase (ESBL) producing Escherichia Coli. Bali Medical Journal, 12(1), 1081–1088.




Search Panel

Maya Permatasari Suyata
Google Scholar
BMJ Journal

Syafri Kamsul Arif
Google Scholar
BMJ Journal

A Husni Tanra
Google Scholar
BMJ Journal

Faisal Muchtar
Google Scholar
BMJ Journal